for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Richter Gedeon Vegyeszeti Gyar Nyrt

GDRB.BU

Latest Trade

6,650.00HUF

Change

-50.00(-0.75%)

Volume

70,584

Today's Range

6,630.00

 - 

6,745.00

52 Week Range

4,702.00

 - 

6,770.00

As of on the Budapest Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Hungary's Richter Q3 net profit HUF 22.2 bln, beats forecast

Nov 8 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt <GDRB.BU>::Q3 NET PROFIT HUF 22.2 BILLION VERSUS HUF 20.9 BILLION IN ANALYST FORECAST BY FINANCIAL NEWS WEBSITE PORTFOLIO.HU.Q3 REVENUE HUF 127.5 BILLION VERSUS HUF 122.1 BILLION ANALYST FORECAST.EXCHANGE RATE CHANGES LIFT REVENUES FROM FOREIGN MARKETS.REVENUE IN FIRST NINE MONTHS RISES BY 11.9% Y/Y TO EUR 1.14 BILLION, HELPED BY SALES IN EU AND U.S..TOTAL NINE-MONTH PROCEEDS FROM ANTI-PSYCHOTIC MEDICINE VRAYLAR $128.4 MILLION.NINE-MONTH OPERATING MARGIN 14.1% VERSUS 15.9% A YEAR EARLIER.RICHTER BOOKS COMPLETE IMPAIRMENT LOSS ON ESMYA U.S. INTANGIBLE ASSET IN Q3.

Hungary's Richter posts HUF 17.1 bln Q2 net profit

Aug 6 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt <GDRB.BU> says in Q2 earnings statement posted on Budapest Stock Exchange web site::Q2 NET PROFIT HUF 17.5 BILLION VERSUS HUF 17.1 BILLION EXPECTED IN SURVEY BY BUSINESS NEWS WEBSITE PORTFOLIO.HU.QUARTERLY PROFIT FALLS BY 27.9 PCT Y/Y.Q2 REVENUE HUF 119.9 BLN VS 116.8 BLN EXPECTED IN PORTFOLIO.HU SURVEY.QUARTERLY REVENUE RISES BY 8.5 PCT Y/Y.IN FIRST HALF, REVENUE FROM BIGGEST MARKET RUSSIA FALLS BY 8.1 PCT Y/Y, U.S. SALES MORE THAN DOUBLE, SALES TO HUNGARY STAGNATE.

Richter, Allergan extend Cariprazine agreement to Latin America

June 21 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt GDRB.BU::.

Richter, Allergan get U.S. approval for expanded use of Vraylar

May 28 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt <GDRB.BU>::RICHTER AND ALLERGAN RECEIVE U.S. FDA APPROVAL FOR EXPANDED USE OF VRAYLAR IN THE TREATMENT OF BIPOLAR DEPRESSION nL4N2342RC.

Richter, CSL subsidiary sign schizophrenia drug sale deal

May 24 (Reuters) - Hungary's Gedeon Richter Plc <GDRB.BU> says in statement published on Budapest Stock Exchange web site::SIGNS LICENSE AGREEMENT TO COMMERCIALISE SCHIZOPHRENIA DRUG CARIPRAZINE IN AUSTRALIA AND NEW ZEALAND WITH CSL <<<CSL.AX>>> SUBSIDIARY SEQIRUS.EXCLUSIVE AGREEMENT SAYS RICHTER RESPONSIBLE FOR PRODUCT SUPPLY, SEQIRUS FOR REGISTRATION AND COMMERCIALISATION IN AUSTRALIA, NEW ZEALAND.RICHTER WILL RECEIVE UNSPECIFIED UPFRONT PAYMENT AND MILESTONE PAYMENTS FROM SEQIRUS.

Hungary's Richter posts HUF 22 bln Q1 net profit

May 10 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt <GDRB.BU>::Q1 NET PROFIT HUF 22 BILLION VERSUS HUF 18.4 BILLION EXPECTED IN SURVEY BY BUSINESS NEWS WEBSITE PORTFOLIO.HU.QUARTERLY PROFIT RISES BY 51.8 PCT Y/Y.Q1 REVENUE HUF 121.6 BLN VS 120.2 BLN EXPECTED IN PORTFOLIO.HU SURVEY.QUARTERLY REVENUE RISES BY 6.7 PCT Y/Y.REVENUE FROM BIGGEST MARKET RUSSIA FALL BY 14 PCT Y/Y, U.S. SALES INCREASE BY 74.7 PCT, SALES TO HUNGARY STAGNATE.

Hungary's Richter signs deal to sell Levosert in Latin America

Feb 12 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt <GDRB.BU>::Has signed a distribution and supply agreement with a wholly-owned subsidiary of Allergan <<<AGN.N>>> to sell its Levosert medicine in Latin America..Sales-related royalties and milestone payments will become payable to Allergan following the launch of the product..

Hungary's Richter posts HUF 16.4 bln Q4 net loss

Feb 7 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt <GDRB.BU>::POSTS 16.4 BILLION FORINT ($58.47 MILLION) Q4 NET LOSS VERSUS 11.5 BILLION FORINT NET PROFIT EXPECTED IN SURVEY BY BUSINESS NEWS WEBSITE PORTFOLIO.HU.BOOKS Q4 IMPAIRMENT LOSS WORTH 24.3 BILLION FORINTS IN RELATION TO UTERINE FIBROID MEDICINE ESMYA.Q4 REVENUE RISES 10.3 PCT Y/Y TO 121.6 BLN FORINTS VS 112.6 BLN EXPECTED IN PORTFOLIO.HU SURVEY.FULL-YEAR REVENUE FALLS 2.7 PCT TO 1.4 BLN EUROS.FULL-YEAR REVENUE FROM UTERINE FIBROID MEDICINE ESMYA FALLS 72 PCT Y/Y TO 25.9 MLN EUROS.FULL-YEAR ROYALTY INCOME FROM ANTI-PSYCHOTIC PRODUCT VRAYLAR RISES 68 PCT TO 75.9 MLN EUROS.2018 OPERATING MARGIN 9.9 PCT VS 4.7 PCT A YEAR EARLIER.

Health Canada Safety Review Finds Possible Link Between Fibristal And Risk Of Liver Injury

Jan 11 (Reuters) - Health Canada::HEALTH CANADA - INFORMING CANADIANS THAT ITS SAFETY REVIEW OF FIBRISTAL FOUND POSSIBLE LINK BETWEEN ITS USE & RISK OF A RARE BUT SERIOUS LIVER INJURY.HEALTH CANADA - INITIATED ITS SAFETY REVIEW OF FIBRISTAL AFTER RECEIVING 4 INTERNATIONAL REPORTS OF LIVER INJURY LEADING TO LIVER TRANSPLANTS.HEALTH CANADA - HAS WORKED WITH THE MANUFACTURER TO UPDATE CANADIAN PRODUCT SAFETY INFORMATION FOR FIBRISTAL, WHICH INCLUDE NEW RESTRICTIONS FOR USE.

Richter's Q3 net profit HUF 9.1 bln, below forecast

Nov 8 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt <GDRB.BU>::Q3 NET PROFIT HUF 9.1 BILLION VERSUS HUF 12.1 BILLION IN ANALYST SURVEY BY BUSINESS NEWS WEBSITE PORTFOLIO.HU.Q3 REVENUES HUF 99.4 BILLION VERSUS HUF 100.2 BILLION IN PORTFOLIO.HU SURVEY.Q1-Q3 REVENUE FROM UTERINE FIBROID MEDICINE ESMYA FALLS 67.6 PCT Y/Y TO 21.9 MLN EUROS.HAS RELAUNCHED TARGETED SALES PROMOTION OF ESMYA IN EARLY SEPT AFTER EUROPEAN REGULATORY PROBE.Q1-Q3 ROYALTY INCOME FROM ANTI-PSYCHOTIC PRODUCT VRAYLAR RISES BY 61.9 PCT TO 52.3 MLN EUROS.PRODUCT LAUNCHED IN FINLAND, SWEDEN, DENMARK AND SWITZERLAND IN OCTOBER, HAS ALSO OBTAINED HUNGARIAN PRICE SUBSIDY IN OCT.REVENUE FROM ROMANIAN BUSINESS FALLS BY 21.8 MLN EUROS DUE TO TEMPORARY SUSPENSION OF LICENCE OF WHOLESALE UNIT.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up